Physician profile
Brian Wong
NPI 1336588482
$15,830.21
in general payments reported to CMS, 2019-2025
31 companies · $7,925 in 2025
The $7,925 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,941 · 2020: $172 · 2021: $564 · 2022: $1,045 · 2023: $1,415 · 2024: $1,768 · 2025: $7,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,595 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,640 · Travel and Lodging: $531 · Consulting Fee: $290 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,595.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,640.00 |
| Travel and Lodging | $530.76 |
| Consulting Fee | $290.00 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,250.46 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $4,411.54 | 2019-2025 | |
| Abbvie INC. | $2,581.28 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Pfizer INC. | $698.89 | 2023-2025 | |
| Genentech USA, INC. | $395.42 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Biogen, INC. | $305.37 | 2019-2024 | Vumerity |
| Amgen INC. | $295.25 | 2022-2025 | Uplizna |
| Celgene Corporation | $230.50 | 2022-2025 | Zeposia |
| Tg Therapeutics, INC. | $207.74 | 2025 | |
| Lilly USA, LLC | $151.93 | 2022-2024 | Amyvid, Emgality, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $146.41 | 2022 | |
| Mallinckrodt Hospital Products INC. | $136.90 | 2023-2025 | Acthar |
| Emd Serono, INC. | $123.90 | 2020-2023 | |
| Sk Life Science, INC. | $114.31 | 2021-2024 | |
| Impel Pharmaceuticals INC. | $103.86 | 2023 | Trudhesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $91.52 | 2021 | |
| Argenx US, INC. | $86.69 | 2025 | Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $78.44 | 2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $58.14 | 2023-2024 | Austedo Xr, Austedo |
| Avadel Cns Pharmaceuticals, LLC | $51.24 | 2024 | Lumryz |
| Alexion Pharmaceuticals, INC. | $50.77 | 2019-2024 | Ultomiris |
| Ucb, INC. | $40.25 | 2025 | Rystiggo, Nayzilam |
| Neurelis, INC. | $37.05 | 2025 | Valtoco |
| Ethicon US, LLC | $35.38 | 2023 | |
| Allergan, INC. | $31.92 | 2019 | |
| Genzyme Corporation | $25.21 | 2025 | |
| Lundbeck LLC | $23.03 | 2024 | Vyepti |
| Livanova USA, INC. | $17.54 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $16.77 | 2024 | |
| Tonix Medicines, INC. | $16.51 | 2025 | Zembrace Symtouch |
| Cycle Pharmaceuticals INC | $15.99 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.